Reply to thread

Message: [QUOTE="Da_Aisijimo_Gou, post: 4201284, member: 264"] Eventually, SENS finished -33% Friday contrary to approval expectations for the company's 6 month monitor. Inconveniently, the CEO's reasonable (conservative?) 2Q profit forecasts spooked some institutional and retail investors alike. However, 2Q profits are primarily or entirely dependent on SENS' pre-existing/ prior-approved 90-day monitor. 3Q-4Q, the newly US FDA approved longer-term monitor (180 days) is projected to markedly increase SENS' profit upside. Doubled up Friday when SENS hit 30% down. When/if it drops more, I plan to add more based on perceived mid- and LT upside potential. [/QUOTE]